Advertisement

Topics

Zymeworks inks deal with Janssen Biotech to develop six bispecific antibodies

07:44 EST 13 Nov 2017 | Topix

Zymeworks inks an agreement with Johnson & Johnson unit Janssen Biotech granting it a global license to research, develop and commercialize up to six bispecific antibodies based on ZYME's Azymetric and EFECT platforms. Under the terms of the deal, ZYME will receive $50M upfront, up to $282M in development milestones, up to $1.12B in commercial milestones and tiered royalties on net sales.

Original Article: Zymeworks inks deal with Janssen Biotech to develop six bispecific antibodies

NEXT ARTICLE

More From BioPortfolio on "Zymeworks inks deal with Janssen Biotech to develop six bispecific antibodies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...